Existing investors Chiesi Ventures and Li-Cor Biosciences came back for the cancer treatment developer's Lundbeckfonden Ventures-led series C.

UK-based ocular oncology developer Aura Biosciences has raised $30m in a series C round co-led by Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Lundbeck.

Venture capital firm Arix Bioscience co-led the round, which also featured pharmaceutical firm Chiesi Group’s corporate venturing arm, Chiesi Ventures, scientific apparatus maker Li-Cor Biosciences and Alexandria Venture Investments, part of real estate investment trust Alexandria Real Estate Equities.

VC firms Ysios Capital and Columbus Venture Partners, growth capital firm Advent Life Sciences and…